IP Library Granted Patent US 11,884,627
Granted Patent B2
US 11,884,627 · App. 18/322,492 · Granted Jan 30, 2024

Compounds and compositions for treating conditions associated with LPA receptor activity

Inventors: Wei Huang (Shanghai, CN); Hui Lei (Shanghai, CN); Zhongmiao Xu (Shanghai, CN); Haizhen Zhang (Shanghai, CN); Qiong Zhang (Shanghai, CN)
Assignee: Lhotse Bio, Inc.
C07D211/66C07C61/39C07C229/18C07C229/28C07D309/14C07D317/54C07D317/58C07D407/12C07C2601/02C07C2601/04C07C2601/08C07C2602/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,884,627
App. No.
18/322,492
Granted
Jan 30, 2024
Kind
B2
Abstract

The present disclosure provides LPA antagonists, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.

Claims (46)

1. A compound which is:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

3. A compound which is:

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a compound of claim 3 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5. A compound, which is:

or a pharmaceutically acceptable salt thereof.

6. A compound, which is:

or a pharmaceutically acceptable salt thereof.

7. A compound, which is:

or a pharmaceutically acceptable salt thereof.

8. A compound, which is:

or a pharmaceutically acceptable salt thereof.

9. A compound, which is:

or a pharmaceutically acceptable salt thereof.

10. A compound, which is:

or a pharmaceutically acceptable salt thereof.

11. A compound, which is:

or a pharmaceutically acceptable salt thereof.

12. A compound, which is:

or a pharmaceutically acceptable salt thereof.

13. A compound, which is:

or a pharmaceutically acceptable salt thereof.

14. A compound, which is:

or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising a compound of claim 5 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

16. A pharmaceutical composition comprising a compound of claim 6 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

17. A pharmaceutical composition comprising a compound of claim 7 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising a compound of claim 8 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising a compound of claim 9 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising a compound of claim 10 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

21. A pharmaceutical composition comprising a compound of claim 11 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising a compound of claim 12 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

23. A pharmaceutical composition comprising a compound of claim 13 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

24. A pharmaceutical composition comprising a compound of claim 14 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

25. A compound, which is:

26. A compound, which is:

27. A compound, which is:

28. A compound, which is:

29. A compound, which is:

30. A compound, which is:

31. A compound, which is:

32. A compound, which is:

33. A compound, which is:

34. A compound, which is:

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2023
From: HUANG, WEI; LEI, HUI; XU, ZHONGMIAO; ZHANG, HAIZHEN; ZHANG, QIONG
To: SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD.
Reel/Frame 065458/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2023
From: SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD.
To: LHOTSE BIO, INC.
Reel/Frame 065458/0953 →
Priority Claims (3)
WO PCT/CN2022/077844 · Feb 25, 2022 · international
WO PCT/CN2022/094839 · May 25, 2022 · international
WO PCT/CN2022/117690 · Sep 8, 2022 · international
Continuity (2)
Continuation PCTCN2023078288 · Feb 25, 2023
Related Publication 20230322675A1 · Oct 12, 2023
Cited By (1)
US 12,428,375